Clinical Trials
2 trialsNCT03063710 2018-05-17
Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan
AstraZeneca
No longer available
NCT03079687 2017-10-25
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AstraZeneca
Approved for marketing